Clinical Features and Therapy of Lymphoblastic Leukemia

Pediatric Hematology: Third Edition

Volumn , Issue , 2007, Pages 450-481

  Smith, Owen P ^a   Hann, Ian M ^b  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^b Camelia Botnar Laboratories   (United Kingdom)

Author keywords

Central nervous system; Eye manifestations; Genitourinary manifestations; Lymphoblastic leukemia; Mediastinal manifestations

Indexed keywords

EID: 84857938873     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987001.ch20     Document Type: Chapter

References (290)

1. Zuelzer WW, Inoue S, Thompson RI et al. Long-term cytogenetic studies in acute leukemia of children: the nature of relapse. Am J Hematol 1976; 1: 143-90.
2. Burchenal JH, Murphy ML. Long term survivors in acute leukemia. Cancer Res 1965; 25: 1491-4.
3. Reiter A, Schrappe M, Ludwig W-D et al. Chemotherapy in 998 unselected childhood ALL patients. Results and conclusions of the multicenter trial ALL-BFM '86. Blood 1994; 84: 3122-33.
4. Gaynon PS, Steinherz PG, Bleyer WA et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol 1993; 11: 2234-42.
5. Rivera GK, Raimondi SC, Williams DL et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-6.
6. Buchanan GR, Rivera GK, Boyett JM et al. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: A Pediatric Oncology Group study. Blood 1988; 72: 1286-92.
7. Henze G, Fengler R, Hartmann R et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166-72.
8. Dordelmann M, Schrappe M, Reiter A et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998; 12: 645-51.
9. Pui CH, Raimondi SC, Borowitz MJ et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 1361-7.
10. Ragab AH, Abdel Mageed A, Shuster JJ et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A Pediatric Oncology Group study. Cancer 1991; 67: 1057-63.
11. Robison LL, Nesbit ME Jr, Sather HN et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children's Cancer Study Group. J Pediatr 1984; 105: 235-42.
12. Mainzer R, Taybi H. Thymic enlargement and pleural effusion: an unusual roentgenographic complex in childhood leukemia. Am J Roentgenol 1971; 112: 35-9.
13. Greydanus DE, Burgert O, Gilchrist GS et al. Hypothalamic syndrome in children with acute lymphocytic leukemia. Mayo Clin Proc 1978; 53: 217-22.
14. Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood 1995; 85: 2537-45.
15. Lauer SJ, Kirchner PAE. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. Am J Pediatr Hematol Oncol 1989; 11: 64-73.
16. Mastrangelo R, Poplack D, Bleyer A et al. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 1986; 14: 191-4.
17. Gilchrist GS, Tubergen DG, Sather HN et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Children's Cancer Group report. J Clin Oncol 1994; 12: 2594-600.
18. Mahmoud HH, Rivera GK, Hancock ML et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993; 329: 314-19.
19. Smith M, Arthur D, Camitta B et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
20. Hustu HO, Aur RJA. Extramedullary leukemia. Clin Haematol 1978; 7: 313-37.
21. Mastrangelo R, Zuelzer WW et al. Chromosomes in the spinal fluid: evidence for metastatic origin of meningeal leukemia. Blood 1970; 35: 227-35.
22. Kataoka A, Shimizu K, Matsumoto T et al. Epidural spinal cord compression as an initial symptom in childhood acute lymphoblastic leukemia: rapid decompression by local irradiation and systemic chemotherapy. Pediatr Hematol Oncol 1995; 12: 179-84.
23. Kim TH, Hargreaves HK, Chan WC et al. Sequential testicular biopsies in childhood acute lymphocytic leukemia. Cancer 1986; 57: 1038-41.
24. Hudson MM, Frankel LS, Mullins J et al. Diagnostic value of surgical testicular biopsy after therapy for acute lymphocytic leukemia. Pediatrics 1985; 107: 50-3.
25. Pui C-H, Dahl GV, Bauman MP et al. Elective testicular biopsy during chemotherapy for childhood leukaemia is of no clinical value. Lancet 1985; ii: 410-12.
26. Schrappe M, Beck J, Brandeis WE et al. Treatment of acute lymphoblastic leukemia in young age: results of multicenter study ALL-BFM 81. Klin Padiatr 1987; 199: 133-8.
27. Steinhardt GF, Steinhardt E. Priapism in children with leukemia. Urology 1981; 18: 604-6.
28. Ritter J, Hiddemann W. Akute Leukämie bei Kindern. Munich: Urban & Schwarzenberger, 1985.
29. Hughes RG, Kay HEM. Major bone lesions in acute lymphoblastic leukemia. Med Pediatr Oncol 1982; 10: 67-70.
30. Kushner DC, Weinstein HJ, Kirkpatrick JA et al. The radiologic diagnosis of leukemia and lymphoma in children. Semin Oncol 1980; 15: 316-34.
31. Murphy RG, Greenberg ML. Osteonecrosis in pediatric patients with acute lymphoblastic leukemia. Cancer 1990; 65: 1717-21.
32. Katz JA, Milton L, Wagner MI et al. Typhlitis: an 18-year experience and postmortem review. Cancer 1990; 65: 1041-7.
33. Gootenberg JE, Abbondanzo SL. Rapid diagnosis of neutropenic enterocolitis by ultrasonsography. Am J Pediatr Hematol Oncol 1987; 9: 222-7.
34. Weetman RM, Baehner RL. Latent onset of clinical pancreatitis in children receiving L-asparaginase therapy. Cancer 1974; 34: 780-5.
35. Shamberger RC, Weinstein HJ, Levery RH et al. The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 1986; 57: 603-9.
36. Boddie AWJ, Bines SD. Management of acute rectal problems in leukemic patients. J Surg Oncol 1986; 33: 53-6.
37. Arico M, Maggiore G, Silini E et al. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. Blood 1994; 84: 2919-22.
38. Schachat A, Markowitz JA. Ophthalmic manifestations of leukemia. Arch Ophthalmol 1989; 107: 697-700.
39. Leonardy NJ, Rupani M, Dent G, Klintworth GK. Analysis of 135 autopsy eyes for ocular involvement in leukemia. Am J Ophthalmol 1990; 109: 436-44.
40. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987; 60: 3071-9.
41. Robb RM, Ervin LD, Sallan SE et al. A pathological study of eye involvement in acute leukemia childhood. Med Pediatr Oncol 1979; 6: 171.
42. Lo Curto M, D'Angelo P, Lumia F et al. Leukemic ophthalmopathy: a report of 21 pediatric cases. Med Pediatr Oncol 1994; 23: 813.
43. Ninane J, Taylor D, Day S et al. The eye as a sanctuary in acute lymphoblastic leukaemia. Lancet 1980; i: 452-3.
44. Reiter A, Schrappe M, Ludwig WD et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood 1992; 80: 2471-8.
45. Lichtman M, Rowe J. Hyperleukocytic leukemias: rheological, clinical and therapeutic considerations. Blood 1982; 60: 279-83.
46. Strauss RA, Gloster ES, Neuberg RW et al. Acute cytoreduction techniques in the treatment of hyperleukocytosis associated with childhood hematologic malignancies. Med Pediatr Oncol 1985; 13: 346-51.
47. Ritter J, Roos N. Special aspects related to invasive fungal infections in children with cancer. Baillière's Clin Infect Dis 1995; 2: 179-204.
48. Lipshultz SE, Colan SD, Sallan SE et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15.
49. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
50. Meeker TC, Hardy D, Hogan T et al. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. Blood 1990; 76: 285-9.
51. Pereira F, Moreno H, Crist W et al. Loffler's endomyocardial fibrosis, eosinophilia, and acute lymphoblastic leukemia. Pediatrics 1977; 59: 950-1.
52. Spier CM, Kjeldsberg CR, Marty J et al. Pre-B-cell acute lymphoblastic leukemia in the newborn. Blood 1984; 64: 1064-6.
53. Dubansky AS, Boyett JM, Pullen J et al. Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group study. Pediatrics 1989; 84: 1068-71.
54. Eguiguren JM, Pui C-H. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1992; 20: 58-60.
55. Hann IM, Evans DIK, Jones PM et al. Bone marrow fibrosis in acute lymphoblastic leukaemia of childhood. J Clin Pathol 1978; 31: 313-15.
56. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-8.
57. Cerezo L, Shuster JJ, Pullen DJ et al. Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study. Am J Clin Pathol 1991; 95: 526-31.
58. Stass SA, Pui C-H, Dahl GV et al. Sudan black B positive acute lymphoblastic leukaemia. Br J Haematol 1984; 57: 413-21.
59. Catovsky D, Greaves MF, Pain C et al. Acid-phosphatase reaction in acute lymphoblastic leukaemia. Lancet 1978; i: 749-51.
60. Ritter J, Gaedicke G, Winkler K, Beckmann H, Landbeck G. Possible T-cell origin of lymphoblasts in acid-phosphatase-positive leukemia. Lancet 1975; ii: 75.
61. Ludwig WD, Bartram CR, Ritter R et al. Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. Blood 1988; 71: 1515-28.
62. Mirro J, Zipf TF, Pui CH et al. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood 1985, 66: 1115-23.
63. Perentesis J, Ramsay N, Ramsay NK et al. Biphenotypic leukemia: immunologic and morphologic evidence for a common lymphoid-myeloid progenitor in humans. J Pediatr 1983; 102: 63-7.
64. Ben-Bassat I, Gale RP. Hybrid acute leukemia. Leukemia Res 1984; 8: 929-36.
65. Greaves MF, Chan LC, Watt SM et al. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood 1986; 67: 1-11.
66. Smith LJ, Curtis JE, Senn JS et al. Lineage infidelity in acute leukemia. Blood 1983; 61: 1138-45.
67. Fink FM, Köller U, Mayer H et al. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1993; 21: 340-6.
68. Ludwig WD, Harbott J, Bartram CR et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: Experience of the BFM study 86. In: Ludwig WD, Thiel E (eds) Recent Results in Cancer Research. Berlin/Heidelberg: Springer-Verlag, 1993, pp. 269-82.
69. Pui C-H, Behm F, Crist WM et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990; 75: 198-202.
70. Wiersma SR, Ortega J, Sobel E et al. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 800-8.
71. Hann I, Vora A, Harrison G et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results of MRC UKALL XI. protocol. Br J Haematol 2001; 113: 103-14.
72. Catovsky D, Matutes E, Buccheri V et al. A classification of acute leukaemia for the 1990s. Ann Hematol 1991; 62: 16-21.
73. Campana D, Hansen-Hagge TE, Matutes E et al. Phenotypic, genotypic, cytochemical and ultrastructural characterization of acute undifferentiated leukemia. Leukemia 1990; 4: 620-4.
74. van Delft F, Saha V. Molecular techniques to improve outcome in childhood ALL. Methods Mol Med 2004; 91: 111-22.
75. Romain SP, Le Coriat M, Berger R. E(12;21): a new recurrent translocation in acute lymphoblastic leukaemia. Genes Chromosomes Cancer 1994; 9: 184-91.
76. Rubnitz JE, Look AT. Molecular genetics of childhood leukaemias. J Pediatr Hematol Oncol 1998; 20: 1-7.
77. Ramakersvan Waerden NL, Pieters R, Loonen AH et al. Tel/AML1 gene fusion is related to in vitro drug sensivity for L-asparaginase in childhood acute lymphoblastic leukaemia. Blood 2002; 96: 1094-9.
78. Paimonid SC, Pui C-H, Hancock ML et al. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukaemia. Leukaemia 1996; 10: 213-24.
79. Jackson JF, Boyett J, Pallen J et al. Favourable prognosis associated with hyper-diploidity in children with acute lymphoblastic leukaemia correlates with extra chromosome 6. Cancer 1990; 66: 1184-9.
80. Heerema NA, Sather NH, Sensel MG et al. Prognostic impact of trisomies 10, 17 and 5 among children with acute lymphoblastic leukaemia and high hyperdiploidy (>50 chromosomes). J Clin Oncol 2000; 18: 1876-87.
81. Golub TR, Slonim DK, Tamayou P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-7.
82. Fourth International Workshop on Chromosomes in Leukaemia. A prospective study of acute non-lymphocytic leukaemia. Cancer Genet Cytogenet 1984; 11: 249-360.
83. Pui C-H, Behm FG, Raimondi SC et al. Secondary acute myeloid leukaemia in children treated for acute lymphoid leukaemia. N Engl J Med 1989; 321: 136-42.
84. Ziemanvan Der Poel S, McCabe NR, Gill HJ et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukaemias. Proc Natl Acad Sci USA 1991; 88: 10735-9.
85. Rubnitz JE. Pui C-H, Downing JR. The role of TEL fusion genes in paediatric leukaemia. Leukaemia 1999; 13: 6-13.
86. Marrow M, Horton S, Kioussis D, Brady H, Williams O. TEL-AML1 promotes development of specifc haemopoietic lineages consistent with preleukaemic activity. Blood 2004; 103: 890-6.
87. Siebert R, Mathiesen P, Harder S et al. Application of interphase fluorescence in situ hybridisation for the detection of the Burkett translocation t(8;14)(q24;q32) in B-cell lymphoma. Blood 1998; 91: 984-90.
88. Mederos LE. Intermediate and high-grade diffuse non-Hodgkin's lymphoma in the working formulation. In: Jaffe ES (ed.) Surgical Pathology of the Lymph Nodes and Related Organs, 2nd edn. Philadelphia: WB Saunders, 1995, pp. 283-343.
89. Hoelzer D, Ludwig W, Eckhard E et al. Improved outcome to adult B-cell acute lymphoblastic leukaemia. Blood 1996; 87: 495-508.
90. Carroll AJ, Crist WM, Parmley RT et al. Pre-B cell leukaemia associated with chromosome translocations 1:19. Blood 1994; 63: 721-4.
91. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukaemia: clinical features and molecular pathogenesis. Blood 1996; 87: 1211-16.
92. Uckum FM, Sensel MG, Sun L et al. Biology and treatment of children T-lineage acute lymphoblastic leukaemia. Blood 1998; 91: 735-46.
93. Campana D, Coustan-Smithe E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-52.
94. Meekev TC, Haroy D, William C et al. Activation of the interleukin-3 gene by chromosomal translocation in acute lymphocytic leukaemia with eosinophilia. Blood 1990; 76: 285-8.
95. Matloub YH, Brunning RD, Arthur DC et al. Severe aplastic anaemia preceding acute lymphoblastic leukaemia. Cancer 1993; 71: 234-68.
96. Riehm H, Gadner H, Henze G et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Haematology and Blood Transfusion. Berlin/Heidelberg: Springer-Verlag, 1990, pp. 439-50.
97. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukaemia: 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993; 329: 1289-95.
98. Pullen J, Boyett J, Shuster J et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1993; 11: 839-49.
99. Veerman AJP, Hählen K, Kamps WA et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996; 14: 911-18.
100. Niemeyer CM, Hitchcock-Bryan S, Sallan SE et al. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol 1985; 12: 122-30.
101. Schorin MA, Blattner S, Gelber RD et al. Treatment of childhood acute lymphoblastic leukaemia: results of Dana-Faber Cancer Institute Children's Acute Lymphoblastic Leukaemia Consortium Protocol 85-01. J Clin Oncl 1994; 12: 740-7.
102. Lilleyman JS, Hann IM, Stevens RF et al. Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. Br J Haematol 1992; 81: 52-7.
103. Steinherz PG, Siegal, Bleyer WA et al. Lymphomatous presentation of childhood acute lymphoblastic leukaemia: a subgroup at high risk of early treatment failure. Cancer 1991; 68: 751-8.
104. Crist W, Pullen J, Dowell B et al. Clinical and biological features predict a poor prognosis in acute lymphoid leukaemias in infants: a Paediatric Oncology Group study. Blood 1986; 67: 135-40.
105. Tubergen DG, Gilchrist GS, O'Brien RT et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol 1993; 11: 527-37.
106. Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 1995; 89: 364-72.
107. Pui C-H, Boyett JM, Hancock ML, Pratt CB, Meyer WH, Crist WM. Outcome of treatment for childhood cancer in black as compared with white children. The St. Jude Children's Research Hospital experience, 1962 through 1992. JAMA 1995; 273: 633-7.
108. Crist WM, Boyett J. Pre B-cell leukemia responds poorly to treatment: a Pediatric Oncology Group study. Blood 1984; 63: 407-14.
109. Crist WM, Caroll AJ, Behm FG et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;q13): a Pediatric Oncology Group study. Blood 1990; 76: 117-22.
110. Pui C-H, Williams DL, Melvin SL et al. Unfavorable presenting clinical and laboratory features are associated with CALLA-negative non-T, non-B lymphoblastic leukemia in children. Leukemia Res 1986; 11: 1287-92.
111. Vannier JP, Bene MC, Faure GC et al. Investigation of the CD 10 (CALLA) negative acute lymphoblastic leukaemia: further description of a group with a poor prognosis. Br J Haematol 1989; 72: 156-60.
112. Kaspers GJ, Smets LA, Pieters R, van Zantwijk CH, van Wering ER, Veerman AJ. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85: 751-6.
113. Raimondi SC, Pui C-H, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 213-24.
114. McLean TW, Ringold S, Neuberg D et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-8.
115. Borkhardt A, Cazzaniga G, Viehmann S et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571-7.
116. Crist W, Carroll A, Link M et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 1990; 76: 489-94.
117. Beyermann B, Agthe AG, Adams H-P et al. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. Blood 1996; 87: 1532-8.
118. Fletscher JA, Lynch EA, Kimball VM et al. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991; 77: 435-9.
119. Ribeiro RC, Abromowitch M, Behm F et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987; 70: 948-53.
120. Roberts WM, Rivera GK, Raimondi SC et al. Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Lancet 1994; 343: 331-2.
121. Lampert F, Harbott J, Ludwig W-D et al. Acute leukemia with chromosome translocation (4;11): 7 new patients and analysis of 71 cases. Blut 1987; 54: 325-35.
122. Pui C-H, Frankel LS, Carroll AJ et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991; 77: 440-7.
123. Aric M, Schrappe M, Harbott J et al. Prednisone good response (PGR) identifies a subset of t(9;22) childhood acute lymphoblastic leukemia (ALL) at lower risk for early leukemia relapse. Blood 1997; 90 (suppl.): 2494-8.
124. Gaynon PS, Bleyer WA, Miller DR et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273-9.
125. Miller DR, Coccia PF. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1989; 7: 1807-15.
126. Riehm H, Reiter A, Schrappe M et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Theraiestudie ALL-BFM 83). Klin Padiatr 1987; 199: 151-60.
127. Schrappe M, Reiter A, Sauter S et al. Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow. Klin Padiatr 1994; 206: 208-21.
128. Biondi A, van Dongen JJM, Seriu T et al. Predictive value of minimal residual disease measurement during remission in childhood acute lymphoblastic leukemia: the results of the International-BFM Study Group (I-BFM-SG). Blood 1997; 10 (suppl.): 1878.
129. Pui C-H, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia: current status and future prospectives. Lancet Oncol 2001; 2: 597-607.
130. Pui C-H, Campana E. New definition of remission in childhood acute lymphoblastic leukaemia. Leukemia 2000; 14: 1483-5.
131. Szczepanski T, Orfao A, van der Velden V et al. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-17.
132. Krejki O, van der Velden V, Bader P et al. Level of MRD prior to stem cell transplantation. Bone Marrow Transplant 2003; 32: 849-51.
133. Moppett J, Burke GA, Steward CG. The clinical relevance of detection of MRD in childhood ALL. J Clin Pathol 2003; 56: 249-53.
134. Cheson B, Dutcher BS. Managing malignancy-associated hyperuricaemia with rasburicase. J Support Oncol 2005; 3: 117-24.
135. Farber S, Diamond LK et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-amionopteroyl-glutamic acid (aminopterin). N Engl J Med 1948; 238: 787-96.
136. Mitchel C, Richards S, Kinsey S et al. Benefit of dexamethasone compared with prednisolone for childhood ALL. Results of the UK-ALL 97 randomized trial. Br J Haematol 2005; 129: 734-45.
137. Boos J, Werber G, Ahlke E et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996; 32A: 1544-50.
138. Nowak-Göttl U, Kuhn N, Wolff JE et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996; 56: 35-8.
139. Freeman AI, Weinberg V, Jones B et al. Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 1983; 308: 477-84.
140. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989; 7: 1816-26.
141. Riccardi R, Balis FM, Poplack DG et al. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986; 3: 319-424.
142. Hann I, Vora A, Richards S. Results from MRC UKALL XI and ALL 97. Leukaemia 2000; 14: 356-63.
143. Lauer SJ, Camitta BM, Leventhal BG et al. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Cancer 1993; 71: 2854-61.
144. Patte C, Philip T, Rodary C et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991; 9: 123-32.
145. Pui C-H, Behn FG, George SL et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136-42.
146. Selawry OS, Hananian J. Vincristine Treatment of Cancer in Children. Jama 1963; 183: 741-6.
147. Clavell LA, Gelber RD, Tarbell MJ et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315: 657-63.
148. Henze G, Langermann HJ, Riehm H et al. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report form the BFM Study Group. Haematol Bluttransfus 1981; 26: 87-93.
149. Camitta B, Mahoney D, Leventhal B et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia. J Clin Oncol 1994; 12: 1383-9.
150. Raimondi SC, Behm FG, Roberson PK et al. Cytogenetics of childhood T-cell leukemia. Blood 1988; 72: 1560.
151. Sallan SE, Gelber RD et al. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. In: Büchner T, Schellong G et al. (eds) Haematology and Blood Transfusion 33. Acute Leukemias II. Heidelberg: Springer-Verlag, 1990, p. 459.
152. Schrappe M, Reiter A, Sauter S et al. Risk-oriented treatment of childhood ALL: favorable outcome despite reduced intensity of treatment in trial ALL-BFM 90. Blood 1997; 90 (suppl.): 2488.
153. Nachman J, Sather H, Lukens J et al. Acute lymphocytic leukemia: clinical investigation and pathophysiology. Augmented Berlin-Frankfurt-Münster (A-BFM) chemotherapy improves event free survival (EFS) for children with acute lymphoblastic leukemia (ALL) and unfavorable presenting features who show a slow early response (SER) to induction chemotherapy. Blood 1997; 90 (suppl.): 2487.
154. Hill FG, Richards S, Gibson B et al. Successful treatment without radiotherapy: results of the CNS treatment trial MRC UKALL XI. Br J Haematol 2004; 124: 33-46.
155. Peylan-Ramu N, Poplack DG, Pizzo PA et al. Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 1978; 298: 815-18.
156. Ochs J, Rivera G, Berg R et al. Central nervous system morbidity following an initial isolated central nervous system relapse and its subsequent therapy in childhood acute lymphoblastic leukemia. J Clin Oncol 1985; 3: 622-6.
157. Clarke M, Graynon P, Hann I et al. CNS-directed therapy for childhood ALL: collaborative group overview of 43 randomised trials. J Clin Oncol 2003; 21: 1798-809.
158. Freeman JE, Johnston PGB et al. Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukaemia. Br Med J 1973; 1: 523.
159. Frei E III, Karon M, Robert H et al. The effectiveness of combinations of antileukemia agents in inducing and maintaining remission in children with acute leukemia. Blood 1965; 26: 642-56.
160. Lonsdale D, Gehan EA, Lane DM et al. Interrupted vs. continued maintenance therapy in childhood acute leukemia. Cancer 1975; 36: 341-52.
161. Chessells JM, Leiper AD, Richards S et al. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child 1987; 62: 172-6.
162. Bleyer WA, Sather HN, Nickerson HJ et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report from the CCSG-161 Study by the Children's Cancer Study Group. J Clin Oncol 1991; 9: 1012-21.
163. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet 1996; 347: 1783-8.
164. George SL, Aur RJA et al. A reappraisal of the results of stopping therapy in childhood leukemia. N Engl J Med 1979; 330: 269-73.
165. Frost L, Richards DS, Goodeve A et al. Late relapsing childhood lymphoblastic leukemia. Blood 1997; 90: 560A.
166. Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol 1991; 78: 196.
167. Miller DR, Leikin S, Palmer MF et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. Cancer 1983; 51: 1041.
168. Steenbergen EJ, Verhagen OJ, van Leeuwen EF et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995; 9: 1726-34.
169. Wasserman R, Galili N, Ito Y et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 1879-88.
170. Beishuizen A, Verhoeven MA, van Wering ER, Hählen K, Hooijkaas H, van Dongen JJ. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-47.
171. Raghavachar A, Ludwig W-D, Bartram CR et al. Clonal variation in childhood acute lymphoblastic leukaemia at early and late relapse detected by analyses of phenotype and genotype. Eur J Pediatr 1988; 147: 503-7.
172. Wright JJ, Poplack DG, Cole D et al. Gene rearrangements as markers of clonal variation and minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1987; 5: 735-41.
173. Baruchel A, Cayuela JM, Macintyre E, Berger R, Sigaux F. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection. Br J Haematol 1995; 90: 85-93.
174. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, von dem Borne AE, van der Schoot CE. Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: implications for monitoring minimal residual disease. Blood 1995; 86: 692-702.
175. Steward CG, Goulden NJ, Katz F et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994; 83: 1355-62.
176. Lampert R, Harbott J, Ritterbach J. Cytogenetic findings in acute leukaemias of infants. Br J Cancer 1992; 66: 20-2.
177. Pui C-H, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-9.
178. Bucsky P, Reiter A, Riehm H et al. Die akute lymphoblastische Leukämie im Säuglingsalter: Ergebnisse aus fünf multizentrischen Therapiestudien ALL-BFM 1970-1986. Klin Padiatr 1988; 200: 177-83.
179. Ochs J, Mulhern RK. Late effects of antileukemic treatment. Pediatr Clinic North Am 1988; 35: 815-33.
180. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989; 11: 93-105.
181. Creutzig U, Ritter J, Vormoor J et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 1996; 10: 1677-86.
182. Neale GA, Pui C-H, Mahmoud HH et al. Molecular evidence for minimal residual bone marrow disease in children with "isolated" extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia 1994; 8: 768-75.
183. Rivera G, Aur RJA, Husto HO et al. Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapy. J Clin Oncol 1983; 1: 471-6.
184. Pui C-H, Raimondi SC, Mirro J et al. Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia. Blood 1986; 68: 1306-10.
185. Nooter K, Sonneveld P. Multidrug resistance (MDR) genes in haematological malignancies. Cytotechnology 1993; 12: 213-30.
186. Buchanan GR, Boyett JM, Pollock BH et al. Improved treatment results in boys with overt testicular relapse during or shortly following initial therapy for acute lymphoblastic leukemia: a Pediatric Oncology Group study. Cancer 1991; 68: 48-55.
187. Bührer C, Hartmann R, Fengler R et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1993; 21: 470-6.
188. Bührer C, Hartmann R, Fengler R et al. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. Blood 1994; 83: 3468-72.
189. Bleyer WA, Sather H, Hammond JD et al. Prognosis and treatment after relapse of acute lymphoblastic leukemia and non-Hodgkin's lymphoma: 1985. A report from the Children's Cancer Study Group. Cancer 1986; 58: 590-4.
190. Rivera GK, Buchanan G, Ochs J et al. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group study. N Engl J Med 1986; 315: 274-8.
191. Barrett AJ, Horowitz MM, Pollock BH et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994; 331: 1253-8.
192. Butturini A, Rivera GK, Gaie RP et al. Which treatment for childhood acute lymphoblastic leukemia in second remission? Lancet 1987; i: 429-32.
193. Casper J, Camitta B, Truitt R et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995; 85: 2345-63.
194. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-8.
195. Pinkerton CR, Mills S, Gale et al. Modified Capizzi maintenance regimen in children with relapsed acute lymphoblastic leukaemia. Med Pediatr Oncol 1989; 14: 69-432.
196. Chessells JM, Bailey CC, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukemia. Lancet 1995; 345: 143-8.
197. Ribeiro RC, Rivera GK, Hudson M et al. An intensive retreatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 1995; 13: 333-8.
198. Winick NJ, Smith SD, Shuster J et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 27-278.
199. Henze G, Fengler R, Hartmann R for the BFM Relapse Study Group. Chemotherapy for relapsed childhood acute lymphoblastic leukemia: results of the BFM Study Group. Haematol Blood Transfusion 1993; 36: 374-9.
200. Bowman WP, Rhodes JA, Husto HO et al. Isolated testicular relapse in acute lymphocytic leukemia of childhood: categories and influence on survival. J Clin Oncol 1984; 2: 924-9.
201. Eden OB, Hardisty RM et al. Testicular disease in acute lymphoblastic leukaemia in childhood. Report on behalf of the Medical Research Council's Working Party on Leukaemia in Childhood. Br Med J 1978; 1: 334.
202. Tiedemann K, Chessells JM. Isolated testicular relapse in boys with acute lymphoblastic leukaemia: treatment and outcome. Br Med J 1982; 285: 1614.
203. Wong KY, Ballard ET, Kisker CT et al. Clinical and occult testicular leukemia in long-term survivors of acute lymphoblastic leukemia. J Pediatr 1980; 96: 569-74.
204. Chessells JM, Eden OB, Bailey C, Lilleyman JS, Richards SM. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials: report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994; 8: 1275-9.
205. Uderzo C, Zurlo G, Zanesco L et al. Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. J Clin Oncol 1990; 8: 672-7.
206. Nachman J, Palmer NF, Sather WH et al. Open-wedge testicular biopsy in childhood acute lymphoblastic leukemia after two years of maintenance therapy: diagnostic accuracy and influence on outcome. A report from Children's Cancer Study Group. Blood 1990; 75: 1051-5.
207. Chessells J, Leiper A, Rogers D. Outcome following late marrow relapse in childhood acute lymphoblastic leukemia. J Clin Oncol 1984; 2: 1099-1091.
208. Chessells JM, Veys P, Kempski H et al. Long term follow up of relapsed childhood ALL. Br J Haematol 2003; 123: 396-406.
209. Bührer C, Hartmann R, Fengler R et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. J Clin Oncol 1996, 14: 2812-17.
210. Somervaille T, Hann I, Harrison G et al. Intraocular relapse of childhood ALL. Br J Haematol 2003; 121: 280-8.
211. Sadowitz PD, Smith SD, Shuster J, Wharam MD, Buchanan GR, Rivera GK. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1993; 81: 602-9.
212. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997; 90: 4933-7.
213. Ramsay NKC, Kersey JH. Indications for marrow transplantation in acute lymphoblastic leukemia. Blood 1990; 75: 815-18.
214. Thomas ed. Marrow transplantation for malignant diseases. J Clin Oncol 1983; 1: 517-31.
215. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-66.
216. Kersey JH, Weisdorf D, Kim T et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high risk refractory acute lymphoblastic leukemia. N Engl J Med 1987; 317: 461-7.
217. Sanders JE, Thomas ED, Buckner CD, Doney K. Marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 1987; 70: 324-6.
218. Blume KG, Forman SJ, Metter GE et al. Total body irradiation and high dose etoposide: a new preparatory regimen for bone marrow transplantation of patients with advanced hematologic malignancy. Blood 1987; 69: 1015-20.
219. Dopfer R, Henze G, Bender-Götze C et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM-and CoALL-protocols: results of the German Cooperative Study. Blood 1991; 78: 2780-4.
220. Suttorp M, Schmitz N, Rister M et al. Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow transplantation in children with poor risk acute leukaemias. Bone Marrow Transplant 1989; 4: 144-8.
221. Woods WG, Ramsay NKC, Haaker R et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing regimens. Bone Marrow Transplant 1990; 6: 9-16.
222. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant receipts with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-30.
223. Dowey S, Armitage S, Rocha V. The London Cord Blood Bank. Br J Haematol 2004; 125: 358-65.
224. Borgmann A, Schmid H, Hartmann R et al. Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. Lancet 1995; 346: 873-6.
225. Schmid H, von Schenck U, Hartmann R, Borgmann A, Henze G. Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non-T/non-B ALL: results of BFM ALL relapse studies. Bone Marrow Transplant 1996; 18 (suppl. 2): 28-30.
226. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-6.
227. Brenner MK. Autologous bone marrow transplantation in childhood acute lymphoblastic leukaemia. Lancet 1995; 346: 856-7.
228. Maidment CG, Greaves MF, Black AG et al. T-cell leukaemia presenting with hyperuricaemia, acute renal failure and gout. Clin Lab Haematol 1983; 5: 423-6.
229. Zusman J, Brown DM, Nesbitt ME et al. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973; 289: 1335-40.
230. Andreoli SP, Cark JH, McGuire WA et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 109: 292-8.
231. Jones DP, Stapleton FB, Pui CH et al. Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med Pediatr Oncol 1990; 18: 283-6.
232. Basade M, Dhar AK, Kulkarni SS et al. Rapid cytoreduction in childhood leukemic hyperleukocytosis by conservative therapy. Med Pediatr Oncol 1995; 25: 204-7.
233. Maurer HS, Steinherz PG, Gaynon PS et al. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol 1988; 6: 1425-32.
234. Nelson SC, Bruggers CS, Kurtzberg J, Friedman HS. Management of leukemic hyperleukocytosis with hydration, urinary alkalinization, and allopurinol. Are cranial irradiation and invasive cytoreduction necessary? Am J Pediatr Hematol Oncol 1993; 15: 351-5.
235. Lo Curto ML, Zingone A, Dini G et al. Leukemic infiltration of the eye: results of therapy in a retrospective multicentric study. Med Pediatr Oncol 1989; 17: 134-9.
236. Murray KM, Goldman JM, Galton DA et al. Ocular involvement in leukaemia. Report of three cases. Lancet 1977; i: 829-31.
237. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1-34.
238. Ott N, Ramsay NKC, Pui CH et al. Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1988; 10: 191-5.
239. Priest JR, Ramsey NKC, Levitt CJ et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100: 984-9.
240. Nowak Göttl U, Auberger K, Göbel U et al. Inherited defects of the protein C anticoagulant system in childhood thromboembolism. Eur J Pediatr 1996; 155: 921-7.
241. Welte K, Reiter A, Mempel K et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996; 87: 3143-50.
242. Feldman S, Hughes WT, Daniel CB et al. Varicella in children with cancer: seventy-seven cases. Pediatrics 1975; 56: 388-97.
243. Rowland P, Wald ER, Mirro JR et al. Progressive varicella presenting with pain and minimal skin involvement in children with acute lymphoblastic leukemia. J Clin Oncol 1995; 13: 1697-703.
244. Zaia JA, Levin MJ, Curtis AC et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147: 171-753.
245. Balfour HH Jr, Bean B, Kirk LE et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448-53.
246. Prober CG, Kirk LE, Keeney RE et al. Acyclovir therapy of chickenpox in immunosuppressed children: a collaborative study. J Pediatr 1982; 101: 622-5.
247. Gray MM, Hann IM, Glass S, Eden OB, Jones PM, Stevens RF. Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective study review. Br Med J 1987; 295: 19-21.
248. Gururangan S, Stevens RF, Morris DJ. Ribavirin response in measles pneumonia. J Infect 1990; 20: 219-21.
249. Hughes I, Jenney MEM, Newton RW, Morris DJ, Klapper PE. Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 68: 775-8.
250. Pifer LL, Hughes WT, Woods D et al. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61: 35-41.
251. Hughes WT, Rivera GK, Lott L et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987; 316: 1627-32.
252. Pasqualini T, Escobar ME, Muriel FS et al. Evaluation of gonadal function following long-term treatment for acute lymphoblastic leukemia in girls. Am J Pediatr Hematol Oncol 1987; 9: 15-22.
253. Siris ES, Leventhal BG, Vaitukaitis JL et al. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976; 294: 1143-6.
254. Lentz RD, Bergstein J, Prem K et al. Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty. J Pediatr 1977; 91: 385-94.
255. Wallace WH, Shalet SM, Lendon M, Morris Jones PH. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl 1991; 14: 312-19.
256. Sklar CA, Robison LL, Kim TH et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1990; 8: 1981-7.
257. Kenney LB, Nicholson HS, Brasseux C et al. Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. Cancer 1996; 78: 169-76.
258. Bessho F, Kinumaki H, Yokota S, Hayashi Y, Kobayashi M, Kamoshita S. Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. Med Pediatr Oncol 1994; 23: 111-15.
259. Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 1986; 68: 1114.
260. Habermalz E, Habermalz H, Henze G et al. Cranial computed tomography of 64 children in continuous complete remission of leukemia: I. Relations to therapy modalities. Neuropediatrics 1983; 14: 144-8.
261. Hara T, Kishikawa T, Goya N et al. Central nervous system complications in childhood leukemia. Am J Pediatr Hematol Oncol 1984; 6: 129-36.
262. Ochs JJ, Parvey LS, Coburn T et al. Serial cranial computed tomography scans in children with leukemia given two different forms of central nervous system therapy. J Clin Oncol 1983; 1: 793-8.
263. Riccardi R, Brouwers P, Popblack DG et al. Abnormal computed tomography brain scans in children with acute lymphoblastic leukemia: serial long-term follow-up. J Clin Oncol 1985; 3: 12-128.
264. Poplack DG, Brouwers P. Adverse sequelae of central nervous system therapy. Clin Oncol 1985; 4: 263.
265. Esseltine DW, Freeman CR, Dube J et al. Computerized tomography brain scans in long-term survivors of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1981; 9: 429-38.
266. Jankovic M, Scotti G, Riccardi R et al. Correlation between cranial computed tomography scans at diagnosis in children with acute lymphoblastic leukaemia and central nervous system relapse. Lancet 1988; ii: 1212-14.
267. Kramer JH, Crittenden MR, Halberg FE, Wara WM, Cowan MJ. A prospective study of cognitive functioning following low-dose cranial radiation for bone marrow transplantation. Pediatrics 1992; 90: 447-50.
268. Obetz WW, Smithson WA, Gilchwist GS et al. Neuropsychologic follow-up study of children with acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 1979; 3: 207-13.
269. Christie D, Leiper AD, Chessells JM, Vargha-Khadem F. Intellectual performance after presymptomatic cranial radiotherapy for leukaemia: effects of age and sex. Arch Dis Child 1995; 73: 136-40.
270. Jannoun L. Are cognitive and educational development affected by age at which therapy is given in acute lymphoblastic leukaemia? Arch Dis Child 1983; 58: 953-8.
271. Chessells JM, Cox TCS, Kendall B, Cavanagh NPC, Jannoun L, Richards S. Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child 1990; 65: 416-22.
272. Meadows AT, Evans AE. Effects of chemotherapy on the central nervous system: a study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood. Cancer 1976; 37: 1079-85.
273. Kumar P, Mulhern RK, Regine WF, Rivera GK, Kun LE. A prospective neurocognitive evaluation of children treated with additional chemotherapy and craniospinal irradiation following isolated central nervous system relapse in acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 1995; 31: 561-6.
274. Longeway K, Mulhern R, Kun L et al. Treatment of meningeal relapse in childhood acute lymphoblastic leukemia: II. A prospective study of intellectual loss specific to CNS relapse and therapy. Am J Pediatr Hematol Oncol 1990; 12: 45-50.
275. Berglund G, Karlberg J, Mellander L et al. A longitudinal study of growth in children with acute lymphoblastic leukaemia. Acta Paediatr Scand 1985; 74: 530-3.
276. Voorhess ML, Brecher ML et al. Growth in children treated for acute lymphoblastic leukaemia. Lancet 1988; i: 460.
277. Kirk JA, Raghupathy P, Vines RH et al. Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukemia. Pediatr Hematol Oncol 1988; 5: 187-93.
278. Robison LL, Nesbit ME Jr. Height of children successfully treated for acute lymphoblastic leukemia: a report from the Late Effects Committee of the Children's Cancer Study Group. Med Pediatr Oncol 1985; 13: 114-21.
279. Moell C, Marky L, Hovi L et al. Cerebral irradiation causes blunted pubertal growth in girls treated for acute leukemia. Med Pediatr Oncol 1994; 22: 375-9.
280. Rappaport R, Brauner R. Growth and endocrine disorders secondary to cranial irridation. Pediatr Res 1989; 25: 561-7.
281. Pasqualim T, McCalla J, Berg S et al. Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukemia. Acta Endocrinol 1991; 124: 375-80.
282. Hanif I, Mahmoud H, Pui C-H. Avascular femoral head necrosis in pediatric cancer patients. Med Pediatr Oncol 1993; 21: 655-60.
283. Pieters R, van der Schans-Dop AM, Veerman AJ et al. Osteonecrosis following chemotherapy for leukemia. Eur J Haematol 1989; 43: 262-4.
284. Leiper AD. Non-endocrine late complications of bone marrow transplantation in children. Br J Haematol 2002; 118: 3-43.
285. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer. Heart 2004; 90: 1214-16.
286. Nygaard R, Garwicz S, Haldorsen T et al. Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. Acta Paediatr Scand 1991; 80: 1220-8.
287. Neglia JP, Meadows AT, Robison LL et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330-6.
288. Tang TT, Holcenberg JS, Camitta BM et al. Thyroid carcinoma following treatment for acute lymphoblastic leukemia. Cancer 1980; 46: 1572-6.
289. Bessho F, Ohta K, Akanuma A. Dosimetry of radiation scattered to thyroid gland from prophylactic cranial irradiation for childhood leukemia. Pediatr Hematol Oncol 1994; 11: 47-53.
290. Kreissmann SG, Gelber RD, Cohen HJ, Clavell LA, Leavitt P, Sallan SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 1992; 70: 2208-13.